SLV-324

SLV-324 is an antibody-drug conjugate from Solve Therapeutics. An antibody-drug conjugate combining a selective targeting antibody, the CloakLink linker and a potent cytotoxic payload, aimed at a membrane receptor protein on solid tumours that the company has not named (distinct from SLV-154's). Its furthest stage is phase 1, for metastatic solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07108114 recruiting. Whether it works in people has not been established unless a trial below reports it.